Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.

International journal of molecular sciences - 17 Apr 2024

Türkmen Deniz, Bowden Jack, Masoli Jane A H, Melzer David, Pilling Luke C

Abstract excerpt

The solute carrier organic anion transporter family member 1B1 (SLCO1B1) encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in SLCO1B1, such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Exome Sequencing
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Simvastatin

Share to Treatment Outcome

Share to UK Biobank

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 38674010
DOI: 10.3390/ijms25084426
PMCID: PMC11050003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.PMID 38674010Read ↗

Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.Semantic proximity Read ↗

Statin treatment effectiveness and the <i>SLCO1B1</i>*5 reduced function genotype: long-term outcomes in women and menSemantic proximity Read ↗

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Semantic proximity Read ↗

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational SettingsSemantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Semantic proximity Read ↗

Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population.Semantic proximity Read ↗

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.Semantic proximity Read ↗

SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.Semantic proximity Read ↗

Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.Semantic proximity Read ↗

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance.Semantic proximity Read ↗

PharmVar GeneFocus: SLCO1B1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.